Kloeckner Pentaplast invests in new lamination facility for pharma applications


Starting operation in 2017 the line in Montabaur, Germany will produce Aclar laminated pharmaceutical films

The Klöckner Pentaplast Group plans to expand its high-barrier film lamination and coating capacities to reinforce its commitment to the global pharmaceutical and medical industries.

The German packaging group is investing an undisclosed sum in a new state-of-the-art system to produce Aclar laminated pharmaceutical films from its site in Montabaur, Germany. The line will start operation early next year.

The new Montabaur line will be used to manufacture the entire kp Pentapharm Aclar product range by the end of 2017.

As a result of this investment, the Klöckner Pentaplast facility in Bern, Switzerland will also have added capacity available to produce PVdC-coated high-barrier pharmaceutical films, which are used generally for solid oral dose forms that require a high moisture barrier due to their formulation, desired shelf life and/or the climates in which they are sold, while continuing to be a backup site for Aclar lamination.

The firm says the plan strengthens its commitment to its global packaging customers by providing improved customer service and security of supply from multiple sites.

Sign up for your free email newsletter

'This capacity expansion is part of Klöckner Pentaplast’s long-term strategy to leverage our global footprint to maximise improvements across the value chain, with a focus on being even more responsive to our pharmaceutical customers’ needs now and in the future,' said Markus Pischulti, Business Director, Pharmaceutical Films EMEA.